Queen City Dermatology in Cincinnati has become the first practice in the region to introduce XERF radiofrequency skin tightening, reflecting broader market penetration of Cynosure's RF platform outside major coastal markets. Regional adoption signals that practices in secondary markets are increasingly investing in premium RF devices to compete on clinical capability and patient outcomes.
Devices & Tech
Queen City Dermatology Becomes First Cincinnati Practice to Offer XERF Radiofrequency
Regional adoption of Cynosure's RF platform expands competitive device landscape.
Regional RF adoption accelerates; first-mover advantage in secondary markets drives competitive positioning.
XERF's fractional RF approach targets dermal remodeling for skin laxity, competing directly with established platforms like Morpheus8 and Secret RF. First-mover advantage in regional markets often translates to patient perception of clinical leadership and can justify premium pricing. For practices considering RF investment, regional adoption patterns offer a useful signal: if competitors in your market are deploying XERF or similar platforms, device differentiation becomes harder and volume-based economics become more critical to justify capital expenditure.
Source: original report ↗
Frequently asked questions
What is XERF radiofrequency and how does it work for skin tightening?
XERF is Cynosure's fractional radiofrequency platform that targets dermal remodeling to treat skin laxity and loose skin. It uses fractional RF energy to stimulate collagen remodeling in the dermis, similar to competing platforms like Morpheus8 and Secret RF, with results typically visible over several weeks as the skin tightens.
How does XERF compare to Morpheus8 and Secret RF?
All three platforms use fractional RF technology for skin tightening and dermal remodeling, making them direct competitors in the premium RF device market. The main differences lie in treatment parameters, downtime, and clinical outcomes, but XERF's entry into secondary markets like Cincinnati suggests comparable efficacy and market viability to established competitors.
Should I invest in XERF if competitors in my area already have it?
If competitors are already deploying XERF or similar RF platforms in your market, device differentiation becomes harder and profitability depends more on treatment volume and operational efficiency than on being first-to-market. You'll need to justify the capital expenditure through higher case volume or premium pricing based on clinical reputation rather than novelty.
What is the first-mover advantage for XERF in regional markets?
Being the first practice to offer XERF in your region can establish patient perception of clinical leadership and justify premium pricing for the procedure. However, this advantage erodes quickly as competitors adopt the same technology, making early adoption most valuable in markets where RF device penetration is still low.
Why are secondary markets like Cincinnati investing in premium RF devices now?
Practices in secondary markets are increasingly adopting premium RF platforms like XERF to compete on clinical capability and patient outcomes, not just price. This shift reflects growing patient demand for advanced skin tightening solutions and the need for regional practices to match the service offerings of larger metropolitan centers.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.